Compare OneSpan Inc (OSPN) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
OneSpan Inc vs Repligen Corporation Common Stock — how do they compare? OneSpan Inc trades at $17.52 (market cap $648.23M), while Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B). The key difference: Repligen Corporation Common Stock is far larger — about 17.4× OneSpan Inc's market cap, and OneSpan Inc pays a 2.96% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold OneSpan Inc for 18 Days and Repligen Corporation Common Stock for 0 Days on average.
| OSPN | RGEN | |
|---|---|---|
Market Cap | $648.23M | $11.31B |
Volume | 466,478 | 1,216,919 |
Sector | Technology | Health |
52-Week High | $18.42 | $194.57 |
52-Week Low | $10.15 | $102.87 |
Typical Hold Time | 18 Days | 0 Days |
Enterprise Value | $617.31M | $11.20B |
Dividend Yield | 2.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $18.20, up 1.96% with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 27.76% net margins and consistent earnings beats, though revenue growth remains modest. Analyst sentiment is positive with 67% buy ratings, while recent news highlights investor interest and product innovation with the DigipassONE launch.
The stock presents value appeal with a P/E under 10 and robust cash generation, but faces execution risks amid competitive pressures and declining net cash flow. Upside potential hinges on subscription revenue growth offsetting hardware declines, with investor focus on Q3 earnings delivery against expectations of $0.236 EPS.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
